NVV1 Stock Chart & Stats
€6.60
€0.02(0.32%)
At close: 4:00 PM EDT
€6.60
€0.02(0.32%)
Day’s Range― - ―
52-Week Range€5.44 - €10.03
Previous CloseN/A
Volume826.00
Average Volume (3M)2.98K
Market Cap
€1.04B
Enterprise Value€833.79
Total Cash (Recent Filing)€790.33M
Total Debt (Recent Filing)€295.06M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 06, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding164,438,130
10 Day Avg. Volume2,086
30 Day Avg. Volume2,984
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.83Price Target Upside48.90% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)-0.4
Revenue Forecast (FY)€348.57M
Bulls Say, Bears Say
Bulls Say
Strategic Partnering MomentumNovavax’s expansion of nonexclusive licenses and MTAs with several top pharma companies materially broadens its addressable opportunities and shares development risk. Durable partnerships create multiple potential milestone and royalty streams, leverage partners’ commercialization capabilities, and institutionalize Matrix-M adoption across indications over the medium term.
Partner-Related Revenue GrowthStrong growth in partner-sourced revenue indicates a transition from direct product reliance to diversified, higher-margin licensing and supply arrangements. That structural shift can stabilize top-line variability, improve gross profitability over time, and tie Novavax’s revenue to partners’ global commercialization efforts rather than sole internal sales execution.
Cash Position And Non‑Dilutive FundingA sizable cash and receivables balance plus recent nondilutive inflows extends runway into 2028, materially reducing immediate refinancing and dilution pressure. This financial cushion gives management time to advance prioritized programs, convert MTAs, and realize partner milestones without forcing near‑term equity raises, supporting durable operational execution.
Bears Say
Negative Shareholders' Equity / Balance Sheet RiskPersistent negative shareholders’ equity is a structural balance sheet weakness that limits financial flexibility. It increases the company’s sensitivity to funding shocks, makes leverage metrics less meaningful, and raises the likelihood of dilutive refinancing if operating performance falters, creating a durable capital‑structure constraint.
Weak Cash Generation / Cash BurnSustained negative operating and free cash flow shows the business is consuming cash rather than generating it from operations. Even with partnerships and nondilutive draws, ongoing cash burn elevates financing risk and places a structural requirement on milestone receipts or cost reductions to restore self‑funding over the medium term.
Reliance On Partners / MTA-to-License UncertaintyNovavax’s business model increasingly depends on partners to convert MTAs into licensed programs and to execute global commercialization. The uncertain timing and probability of conversion create durable operational risk: delays or partner deprioritization would defer milestone and royalty receipts and weaken the expected partner‑driven revenue trajectory.
Novavax News
NVV1 FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was €5.44 and its highest was €10.03 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is €1.04B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on May 06, 2026. The company reported -€0.052 earnings per share for the quarter, beating the consensus estimate of -€0.21 by €0.158.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.33.
How many shares outstanding does Novavax have?
Novavax has 164,438,130 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -€0.052 in its last earnings report, beating expectations of -€0.21. Following the earnings report the stock price went up 18.955%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in DE:NVV1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€9.83 (48.90% Upside)
€9.83 (48.90% Upside)
Blogger Sentiment
Bullish
DE:NVV1 Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.32%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVV1 Company Deck
NVV1 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all DE:NVV1 earnings summariesNVV1 Stock 12 Month Forecast
Average Price Target
€9.83
▲(48.90% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―